Evidence map›Paper›PMID 39703154›Full record

ReviewNanomedicine (London, England)2025

Innovative nanocarrier systems for enhanced delivery of phyto-active compounds in cancer therapy.

Khusbu Dwivedi, Ankit Sahoo, Waleed H Almalki, Salem Salman Almujri, Alhussain Aodah, Nabil K Alruwaili, Safia Obaidur Rab, Abdulkareem Ali Alanezi, Esraa M Haji, Md Abul Barkat and 2 more

Abstract readReview
In one paragraph

Review in Nanomedicine (London, England), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
  4. Review
  5. Article
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Khusbu DwivediDepartment of Pharmaceutics, Shambhunath Institute of Pharmacy, Prayagraj, India.
Ankit SahooDepartment of Pharmaceutical Sciences, Shalom Institute of Health & Allied Sciences, Sam Higginbottom University of Agriculture, Technology & Sciences, Allahabad, India.
Waleed H AlmalkiDepartment of Pharmacology and Toxicology, College of Pharmacy, Umm Al-Qura University, Makkah, Saudi Arabia.
Salem Salman AlmujriDepartment of Pharmacology, College of Pharmacy, King Khalid University, Asir-Abha, Saudi Arabia.
Alhussain AodahCollege of Pharmacy, Prince Sattam Bin Abdulaziz University, Alkharj, Saudi Arabia.
Nabil K AlruwailiDepartment of Pharmaceutics, College of Pharmacy, Jouf University, Sakakah, Saudi Arabia.
Safia Obaidur RabDepartment of Clinical Laboratory Science, College of Applied Medical Science, King Khalid University, Abha, Saudi Arabia.
Abdulkareem Ali AlaneziDepartment of Pharmaceutics, College of Pharmacy, University of Hafr Al-Batin, Hafr Al Batin, Saudi Arabia.
Esraa M HajiDepartment of Pharmaceutical Chemistry, College of Pharmacy, University of Hafr Al Batin, Hafr Al Batin, Saudi Arabia.
Md Abul BarkatDepartment of Pharmaceutics, College of Pharmacy, University of Hafr Al-Batin, Hafr Al Batin, Saudi Arabia.ORCID 0000-0001-6009-5222
Tanuja SinghCentre for Interdisciplinary Research in Basic Sciences, Jamia Millia Islamia, Jamia Nagar, New Delhi, India.
Mahfoozur RahmanDepartment of Pharmaceutical Sciences, Shalom Institute of Health & Allied Sciences, Sam Higginbottom University of Agriculture, Technology & Sciences, Allahabad, India.ORCID 0000-0002-5616-4026

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Millions of people worldwide suffer from cancer, facing challenges such as treatments affecting healthy cells, suboptimal responses, adverse effects, recurrence risk, drug resistance, and nonspecific targeting. Chemoresistance leads to fatalities, but phytoactives show promise in cancer management despite limitations such as high metabolism, poor absorption, and high dosage requirements. Challenges in the large-scale isolation of phytoactive compounds, solubility, bioavailability, and targeting limit their development. Recent developments, including carbohydrate, lipid, and protein-based nanoparticles, have enhanced cancer treatment by improving the bioavailability and targeted delivery of phytoactives such as polyphenols, alkaloids, sulfur-containing compounds, flavonoids, and terpenes. Despite advancements, clinical application faces hurdles such as poor bioavailability and inconsistent immune responses. This article discusses the promise of phytoactive-loaded nanoformulations in cancer management, highlighting targeted drug delivery, unmet needs, and challenges. Further research is needed to overcome these challenges and fully understand the potential of phytoactives in cancer management.

Indexed as

NanoparticlesNeoplasmsAnimalsAntineoplastic Agents, PhytogenicBiological AvailabilityDrug CarriersDrug Delivery SystemsHumansNanoparticle Drug Delivery SystemPhytochemicalsAntineoplastic Agents, PhytogenicDrug CarriersNanoparticle Drug Delivery SystemPhytochemicalsCancerchemotherapyliposomesphytoactivespreclinical challengessolid lipid nanoparticlestargeted therapyunmet need

Identifiers

PMID39703154
PMCPMC11703466

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.